FDA Approach On Warning Letters, Drug Approvals Could Change Post-Caronia
Industry attorneys suggest FDA warning letters will become more carefully worded and potentially easier to challenge on First Amendment grounds in the wake of the Second Circuit’s decision in the landmark off-label promotion case. FDA’s view of the evidence needed to demonstrate drug efficacy also could evolve.
You may also be interested in...
If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
Advisory committee votes 24-2 against approval of Intellipharmaceutics’ Aximris XR due to concerns the extended-release oxycodone formulation may be more susceptible to intranasal abuse than existing products; Esteve fares better with its tramadol/celecoxib combination, securing a tie vote on approval for acute pain.